ZeBlast strives to generate a catalogue of zebrafish blood, heart and brain diseases models with full genotypic and phenotypic validation, making them available to customers off-the-shelf, thereby significantly reducing the lag time to product availability.
We have generated transgenic fish reminiscent of human blood cancers carrying combinations of gene mutations. These transgenic zebrafish exhibit following traits that are consistent with human leukaemia:
These are considered prototypes based on mutation combinations frequently identified in human blood cancers with full clinicopathologic and transcriptomic validations. A U.S. provisional patent application for the zebrafish model that may contain two or more of the AML-associated gene mutations has been filed.
In the development of blood cancer models, we have generated or acquired fish lines carrying transgenes or mutations characteristic of CHIP. CHIP is caused by somatic mutations of haematopoietic stem cells (HSC) and different mutation combinations give rise to diverse complications among the elderly. CHIP models are worth to develop because:
CHIP models will become important assets to expedite the discovery of drugs that prevent aging-related diseases.
Our products focus on blood cancer models and they have been characterized to ensure faithful recapitulation of human diseases and are available off-the-shelf, providing models for both industrial and academic customers to begin their drug discovery almost immediately.
Drug discovery begins immediately
A lag-time of 2-3 years before drug discovery begins
Zebrafish are an excellent model organism for drug discovery due to their genetic and physiological similarities to humans. Zeblast zebrafish models have been rigorously validated, ensuring and guaranteed that they are reliable and efficient for drug screening.
